Resonance tests FerriScan
Tuesday, 01 July, 2008
WA-based diagnostics company Resonance Health (ASX: RHT) has lodged an application with the Australian Medical Services Advisory Committee seeking reimbursement for its FerriScan iron test in Australia.
The company has already had some public funding success overseas, with the Whittington Hospital in London receiving funding approval from the British National Health Service [NHS].
FerriScan is used in to test for and measure levels of iron overload in the liver, caused by regular blood transfusions received by patients with sickle cell disease, thalassemia major and myelodysplastic syndromes.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
